Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2

 Agnieszka Dabrowska, Artur Szczepanski, Pawel Botwina, Natalia Mazur-Panasiuk, Helena Jirincova, Lukasz Rabalski, Tomas Zajic, Grzegorz Popowicz,  

View ORCID ProfileKrzysztof Pyrc

doi: https://doi.org/10.1101/2021.12.21.473268

This article is a preprint and has not been certified by peer review [what does this mean?].

PDF: https://www.biorxiv.org/content/10.1101/2021.12.21.473268v1.full.pdf

Abstract

The Omicron variant of the SARS-CoV-2 virus was first detected in South Africa in November 2021. The analysis of the sequence data in the context of earlier variants suggested that it may show very different characteristics, including immune evasion and increased transmission. These assumptions were partially confirmed, and the reduction in protection in convalescent patients and vaccinated individuals have been confirmed. Here, we have evaluated the efficacy of antivirals against SARS-CoV-2 variants, Omicron, Delta, and the early 2020 isolate.

Competing Interest Statement

ACF and its derivatives and their use against beta-coronaviruses are protected by European patent application no. 20214108.1 submitted by the authors of this manuscript.

https://www.biorxiv.org/content/10.1101/2021.12.21.473268v1